Redx to present new scientific data at ESMO 2017

31 August 2017

Redx Pharma Plc will present a poster on their planned first-in-human clinical trial for RXC004 at the European Society for Medical Oncology (ESMO) Annual Meeting, September 8-12, 2017, in Madrid.

Session Date & Time September 9, 2017, 13:15-14:15 GMT+1h
Session Title Gastrointestinal Tumors, Colorectal
Presentation Title Identification of an RNF43 mutated gastric cancer patient population with potential sensitivity to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay for patient screening
Session Location Hall 8
Abstract # 692P
First author Matilda Bingham
Abstract online https://cslide.ctimeetingtech.com/library/esmo/browse/search/...

Iain Ross, Chairman, commented: We're delighted to present new scientific data on our most advanced program, the Porcupine inhibitor RXC004 as it moves closer to the clinic. We have a strong portfolio of research assets and continue to look for novel opportunities in several therapeutic classes in oncology and immunology.